The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
Etanercept (Enbrel) will be added to standard therapy for acute Graft-versus-Host Disease to
see if the effectiveness of standard therapy can be improved.
Partial Funding Source- FDA OOPD
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center